SynthesisNeurosurgical review2024
An updated systematic review of neuroprotective agents in the treatment of spinal cord injury.
Synthesis in Neurosurgical review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Platelet-rich plasma in anterior cruciate ligament reconstruction: An updated systematic review and quantitative meta-analysis of randomized controlled trials.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Pooled it
- Comparative efficacy and safety of four immunomodulatory agents for acute spinal cord injury: a systematic review and Bayesian network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Barbed sutures versus conventional sutures for wound closure in spine surgeries: a systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- Automated segmentation of neurons and spinal cord structures in immunofluorescence images using SpineDL.Scientific reports · 2026Article
- Systemic Interleukin-4 Application Promotes Functional Recovery and Reprograms Neuroinflammatory and Molecular Responses after Spinal Cord Injury in Rats.Theranostics · 2026Article
- Potential Pharmacologic Treatments in Spinal Cord Injury: A Narrative Review.Korean journal of neurotrauma · 2025Review
- A Meta-Analysis and Systematic Review on the Use of Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis Management.Indian journal of orthopaedics · 2025Review
- Advances and New Therapies in Traumatic Spinal Cord Injury.Journal of clinical medicine · 2025Review
- Global trends and hotspots of neuromodulation in spinal cord injury: a study based on bibliometric analysis.Journal of orthopaedic surgery and research · 2025Article
- Current and emergent therapies targeting spinal cord injury.Brain & spine · 2025Review
- UTX/Top2β axis mediated spinal cord microvascular endothelial cells senescence exacerbates spinal cord injury.PloS one · 2025Article
- Critical Care of Spinal Cord Injury.Current neurology and neuroscience reports · 2024Review
- Letter to the editor: Systematic review on neuroprotective agents in spinal cord injury.Neurosurgical review · 2024Article
- Enhancing mitophagy by ligustilide through BNIP3-LC3 interaction attenuates oxidative stress-induced neuronal apoptosis in spinal cord injury.International journal of biological sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review aims to summarize the findings from all clinical randomized trials assessing the efficacy of potential neuroprotective agents in influencing the outcomes of acute spinal cord injuries (SCI). Following the PRISMA guidelines, we conducted comprehensive searches in four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) up to September 5th, 2023. Our analysis included a total of 30 studies. We examined the effects of 15 substances/drugs: methylprednisolone, tirilazad mesylate, erythropoietin, nimodipine, naloxone, Sygen, Rho protein antagonist, granulocyte colony-stimulating factor, autologous macrophages, autologous bone marrow cells, vitamin D, progesterone, riluzole, minocycline, and blood alcohol concentration. Notable improvements in neurological outcomes were observed with progesterone plus vitamin D and granulocyte colony-stimulating factor. In contrast, results for methylprednisolone, erythropoietin, Sygen, Rho Protein, and Riluzole were inconclusive, primarily due to insufficient sample size or outdated evidence. No significant differences were found in the remaining evaluated drugs. Progesterone plus vitamin D, granulocyte colony-stimulating factor, methylprednisolone, Sygen, Rho Protein, and Riluzole may enhance neurological outcomes in acute SCI cases. It is worth noting that different endpoints or additional subgroup analyses may potentially alter the conclusions of individual trials. Therefore, certain SCI grades may benefit more from these treatments than others, while the overall results may remain inconclusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.